{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:55:21Z","timestamp":1781513721866,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000654","name":"Marie Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.radonc.2026.111385","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:29:49Z","timestamp":1768717789000},"page":"111385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19\u00a0Gy for localized prostate cancer"],"prefix":"10.1016","volume":"216","author":[{"given":"Wiwatchai","family":"Sittiwong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-9583","authenticated-orcid":false,"given":"Amarnath","family":"Challapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9567","authenticated-orcid":false,"given":"Peter","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 5","key":"10.1016\/j.radonc.2026.111385_b0005","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111385_b0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.prro.2023.09.007","article-title":"Radiation therapy summary of the AUA\/ASTRO guideline on clinically localized prostate cancer","volume":"14","author":"Deville","year":"2024","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111385_b0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ijrobp.2013.11.241","article-title":"Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy","volume":"88","author":"Georg","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.radonc.2026.111385_b0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.brachy.2013.03.003","article-title":"A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer","volume":"12","author":"Spratt","year":"2013","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.radonc.2026.111385_b0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.radonc.2018.03.022","article-title":"High dose rate brachytherapy for prostate cancer: a prospective toxicity evaluation of a one day schedule including two 13.5\u00a0Gy fractions","volume":"127","author":"Nagore","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111385_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770959","article-title":"High-Dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up","volume":"11","author":"Behmueller","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0045","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2017.09.038","article-title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","volume":"126","author":"Strouthos","year":"2018","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.brachy.2020.10.009","article-title":"HDR brachytherapy as monotherapy for prostate cancer: a systematic review with meta-analysis","volume":"20","author":"Viani","year":"2021","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.radonc.2026.111385_b0055","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.brachy.2018.06.002","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localized prostate cancer: toxicity and 6-year biochemical results","volume":"17","author":"Prada","year":"2018","journal-title":"Brachytherapy"},{"issue":"6","key":"10.1016\/j.radonc.2026.111385_b0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/jcb.2020.101685","article-title":"High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience","volume":"12","author":"Soatti","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.radonc.2026.111385_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110381","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update","volume":"198","author":"Hudson","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111385_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.09.007","article-title":"Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost","volume":"154","author":"Alayed","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111385_b0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.radonc.2021.03.018","article-title":"Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial","volume":"159","author":"Armstrong","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111385_b0080","first-page":"64","article-title":"Single fraction of HDR brachytherapy for prostate cancer: results of the SiFEPI phase II prospective trial","volume":"37","author":"Hannoun-Levi","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111385_b0085","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/pros.24548","article-title":"LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: a prospective study","volume":"83","author":"Jimenez-Garcia","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.radonc.2026.111385_b0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.radonc.2020.12.021","article-title":"Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial","volume":"156","author":"Corkum","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0095","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7150\/jca.104279","article-title":"Single-fraction high-dose-rate brachytherapy as monotherapy for localized prostate cancer: long-term follow-up study based on meta-analysis","volume":"16","author":"Xiao","year":"2025","journal-title":"J Cancer"},{"issue":"6","key":"10.1016\/j.radonc.2026.111385_b0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00066-023-02063-z","article-title":"Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis","volume":"199","author":"Zeng","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2026.111385_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110426","article-title":"Single-dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer","volume":"199","author":"Hoskin","year":"2024","journal-title":"Radiother Oncol"},{"issue":"1065","key":"10.1016\/j.radonc.2026.111385_b0110","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150981","article-title":"Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions","volume":"89","author":"Fellin","year":"2016","journal-title":"Br J Radiol"},{"issue":"15","key":"10.1016\/j.radonc.2026.111385_b0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0120","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2011.07.009","article-title":"PSA nadir of <0.5 ng\/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure","volume":"83","author":"Ko","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.radonc.2026.111385_b0125","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2008.05.059","article-title":"Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial","volume":"73","author":"King","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.radonc.2026.111385_b0130","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ijrobp.2010.04.046","article-title":"Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer","volume":"80","author":"Morton","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.radonc.2026.111385_b0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.radonc.2016.10.019","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy","volume":"122","author":"Morton","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111385_b0140","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/5729185","article-title":"Alterations of sexual and erectile functions after brachytherapy for prostate cancer based on patient-reported questionnaires","volume":"2024","author":"Gesztesi","year":"2024","journal-title":"Prostate Cancer"},{"issue":"10","key":"10.1016\/j.radonc.2026.111385_b0145","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4329\/wjr.v9.i10.389","article-title":"Lymph node imaging in initial staging of prostate cancer: an overview and update","volume":"9","author":"Zarzour","year":"2017","journal-title":"World J Radiol"},{"key":"10.1016\/j.radonc.2026.111385_b0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1748-717X-8-190","article-title":"A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured","volume":"8","author":"Meijer","year":"2013","journal-title":"Radiat Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111385_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.euo.2023.11.002","article-title":"Prognosis of Gleason score 9-10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study","volume":"7","author":"Egevad","year":"2024","journal-title":"Eur Urol Oncol"}],"updated-by":[{"DOI":"10.1016\/j.radonc.2026.111520","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000}}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402600023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402600023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:21:27Z","timestamp":1781511687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402600023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S016781402600023X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111385","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes from a multicentre study of HDR monotherapy with a single fraction of 19\u00a0Gy for localized prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111385"}}